Бельдиев С. Н., Медведева И. В., Платонов Д. Ю., Труфанова Г. Ю. Исследования антикоагулянтной терапии у «хрупких» пожилых пациентов: проблемы терминологии и методологии. Рациональная Фармакотерапия в Кардиологии. 2019;15(2)
1. Vorobyeva NM, Tkacheva ON. Anticoagulant therapy in “fragile” elderly patients: current state of the problem. Rational Pharmacotherapy in Cardiology. 2018;14(6):908-16 (In Russ.). doi:10.20996/1819-6446-2018-14-6-908-916.
2. Büller HR, Prins MH, Lensin AW, et al.; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi:10.1056/NEJMoa1113572.
3. Prins MH, Lensing AW, Bauersachs R, et al.; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21. doi:10.1186/1477-9560-11-21.
4. Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56. doi:10.1093/gerona/56.3.m146.
5. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. doi:10.1186/1471-2318-8-24.
6. Bel'diev SN, Platonov DJu. A typical mistake in prescribing rivaroxaban to elderly patients with atrial fibrillation. Russian Heart Journal. 2017;16(3):207-12 (In Russ.). doi:10.18087/rhj.2017.3.2345.
7. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864-72. doi:10.1093/eurheartj/ehu046.
8. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72. doi:10.1161/CIRCULATIONAHA.110.004747.
9. Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138-46. doi:10.1161/CIRCULATIONAHA.113.005008.
10. Lauw MN, Eikelboom JW1, Coppens M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015-23. doi:10.1136/heartjnl-2016-310358.
11. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018 Apr 13;7(8):e008643. doi:10.1161/JAHA.118.008643.
12. Martsevich SYu, Kutishenko NP. Randomized clinical trials and observational studies: the ratio in the hierarchy of evidence of the efficacy of drugs. Rational Pharmacotherapy in Cardiology. 2016;12(5):567-73 (In Russ.). doi:10.20996/1819-6446-2016-12-5-567-573.
13. Martsevich SYu, Lukina YV, Kutishenko NP. Once again about the hierarchy of evidences in medicine or whether it is possible to choose the most effective and safe drug with the help of observational studies. Rational Pharmacotherapy in Cardiology. 2017;13(2):270-4 (In Russ.). doi:10.20996/1819-6446-2017-13-2-270-274.
14. Arutyunov GP, Arhipov MV, Bakalov IN, et al. Place and significance of observational studies of NOACs in patients with non-valvular atrial fibrillation from the standpoint of evidence-based medicine. Russian Heart Journal. 2016;15(6):441-7 (In Russ.). doi:10.18087/rhj.2016.6.2297.
15. US Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate): full prescribing information. Revised: 03/2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022512s035lbl.pdf. Accessed by March 3, 2019.
16. The State Register of Medical Products. Pradaxa prescribing information (In Russ.). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bb76178c-cf95-4cbd-9883-6ba08ccb508d&t=. Accessed by March 3, 2019.
17. Coleman CI, Turpie A, Bunz TJ, Sood N. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2018 March 20;71(S11):A290. doi:10.1016/S0735-1097(18)30831-3.
